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Abstract
In a prospective long-term follow-up of patients with locally advanced rectal cancer treated with radio-
chemotherapy and surgery, downstaging of tumor and nodal status were signiﬁcant predictors for longer
progression-free and overall survival. A high local control rate of trimodal treatment comes at the cost of
considerable long-term toxicity, with patient-reported dissatisfaction of bowel function even years after
treatment.
Background: The risk/beneﬁt ratio of any treatment can only be fully assessed if long-term results of both efﬁcacy and
toxicity are taken into account. Whereas the combined modality treatment of locally advanced rectal cancer (LARC)
has considerably improved prognosis, particularly with regard to local control, long-term results—including patient-
reported outcomes—are underreported. Patients and Methods: Patients with LARC treated within a multicenter
single-arm phase II study were prospectively assessed for at least 5 years after surgery. Study treatment consisted of
capecitabine and oxaliplatin prior and concurrent to preoperative pelvic radiotherapy followed by total mesorectal
excision. Progression-free survival time (ﬁrst endpoint), overall survival time, and pattern of relapse were analyzed in
the whole study population and in pre-planned exploratory subgroups. Patient-reported outcomes, including overall
satisfaction with bowel, stoma, and urinary function, were assessed in 6-month intervals. Results: Five-year
progression-free and overall survival rate was 61% (95% conﬁdence interval [CI], 46%-73%) and 78% (95% CI, 63%-
87%), respectively. Distant to local recurrence rate was 3:1, with only 8% of patients relapsing locally. Main predictors
for recurrence in univariate analyses were tumor downstaging (hazard ratio, 0.16; 95% CI, 0.05-0.56; P ¼ .0011) and
nodal downstaging (hazard ratio, 0.17; 95% CI, 0.06-0.52; P ¼ .0005). The self-reported burden of symptoms related
to bowel function was high in up to one-third of patients. A total of 28% of patients were dissatisﬁed with their urinary,
bowel, or stoma function for at least 1 observation period. Conclusion: Combined-modality treatment of LARC results
in a high and durable local disease control rate, especially in patients with tumor and/or nodal downstaging, at the cost
of relevant long-term toxicity. Long-term care is required for a proportion of patients with poor gastrointestinal and/or
urinary function after multimodality therapy. Reporting of long-term follow-up, including patient-recorded outcomes
should be mandatory for future trials in LARC.
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Age, years, median (range) 61 (35-77)














Upper rectum 15 (29)
Mid-rectum 27 (53)
Lower rectum 17 (34)
aPatients with tumor location upper/middle or middle/lower are subjects of both groups. They
count twice in total number of patients.The prognosis for patients with rectal cancer has considerably
improved during the past decade.1 Today’s standard multidisci-
plinary approach, allowing for accurate preoperative staging, opti-
mized surgery with universal adoption of total mesorectal excision
and improved radiotherapy techniques, was key to this step for-
ward.2,3 The majority of patients with localized—including locally
advanced—rectal cancer will become long-term survivors.4 Even
patients with stage 4 disease and few resectable distant metastases
from rectal cancer have an approximately 20% probability to survive
for more than 5 years after diagnosis.5 This prospect needs to shift
our focus away from short-term treatment results towards long-term
outcomes, allowing a thorough assessment whether efﬁcacy results
outweigh long-term treatment sequelae.
Whereas the treatment approach for patients with locally
advanced rectal cancer (LARC) (ie, T3/T4 tumors with or without
nodal involvement) is somewhat controversial, results of the pivotal
German rectal cancer trial6,7 made combined radiochemotherapy
followed by surgery a standard approach. Despite efforts to
improve treatment efﬁcacy quoad vitam by incorporating new
drugs into the radiochemotherapy regimen,8-12 the backbone of
combined preoperative treatment is still ﬂuoropyrimidine single
agent treatment, either intravenously or in its oral form (ie, cape-
citabine).13 However, few of these recent trials14,15 report long-
term outcomes. We prospectively assessed long-term efﬁcacy and
side effects in patients with LARC treated in a phase II trial10 with
capecitabine and oxaliplatin prior and concurrent to preoperative
pelvic radiotherapy.Table 2 Treatment of All 51 Patients
Treatment N [ 51 (%)
Underwent surgery 51 (100)
Sphincter preservation 42 (82)
Selected grade 3/4 adverse eventsa 28 (55)
Tumor downstaging 22 (43)
Nodal downstaging 24 (47)
Complete pathologic response (Dvorak 3 or 4) 11 (22)
Adjuvant chemotherapy 30 (59)
XELOX or FOLFOX 12 (40%)
Capecitabine or 5FU single agent 14 (47%)
Other 4 (13%)
Abbreviations: FOLFOX ¼ oxaliplatin with ﬂuorouracil (5FU) and folinic acid; XELOX ¼ cape-
citabine plus oxaliplatin.
aGrade 3 or 4 diarrhea or lymphocytopenia during neoadjuvant chemoradiation.Patients and Methods
All patients were treated in a prospective, multicenter, single-arm
phase II study with preoperative radiochemotherapy and surgery.10
Patients with histologically conﬁrmed locally advanced (ie, endo-
sonographically or magnetic resonance imaging-assessed T3/4) tu-
mors with or without nodal involvement, were included. Treatment
consisted of 1 cycle of capecitabine plus oxaliplatin (XELOX)
chemotherapy (capecitabine 1000 mg/m2 twice a day on days 1 to
14 and oxaliplatin 130 mg/m2 on day 1), followed by radiotherapy
(1.8 Gy fractions 5 days per week for 5 weeks) plus 2 concomitant
cycles of capecitabine plus oxaliplatin (CAPOX; capecitabine 825
mg/m2 twice daily on days 1 to 14 and oxaliplatin 50 mg/m2 on
days 1 and 8; every 3 weeks). Surgery was recommended 5 weeks
after the end of radiochemotherapy. The preferred approach of
radical resection was total mesorectal excision with sphincter pres-
ervation. Administration of adjuvant chemotherapy was left to the
treating oncologists’ discretion. Details on patients, methods,
treatment, and short-term results have been published.10
Long-term follow-up was not part of the initial protocol. There-
fore, patients were reconsented for this ethics-approved follow-up
study. Patients who were lost to follow-up or died before reconsenting
were also included in the survival analyses. The Expert Commission
of the Professional Secret in Medical Research of the Swiss Federal
Ofﬁce for Public Health (FOPH) gave authorization for this.
Patients and treating physicians were contacted once yearly after
completion of primary treatment, and the following data were
collected: (1) Efﬁcacy parameters: date and location (local/distant)nical Colorectal Cancer Month 2016of recurrence was recorded for the primary outcome of progression-
free survival (PFS; time between ﬁrst day of neoadjuvant treatment
until recurrence, progression, or death). Survival status was recorded
for the secondary outcome of overall survival (OS); (2) Long-term
side effects: bowel function was assessed in terms of number of
bowel movements per day and regular use of constipating agents as
well as fecal incontinence (yes/no). Urinary function was assessed in
terms of presence or absence of incontinence. Overall patient-
reported satisfaction was assessed in terms of satisfaction with
bowel, stoma, and urinary function on a 4-point scale (very good,
Figure 1 A, Progression-Free Survival; B, Overall Survival
Abbreviations: CI ¼ conﬁdence interval; OS ¼ overall survival; PFS ¼ progression-free survival.
Viviane Hess et algood, poor, very poor); (3) Adherence to National Guidelines:
modality and frequency of all performed follow-up examinations
were recorded and compared with the Swiss Society of Gastroen-
terology guidelines (www.sggssg.ch).16,17
PFS and OS curves were calculated according to the Kaplan-
Meier method for all patients. Exploratory subgroup analyses were
preplanned for the following factors (groups, yes/no): tumor
downstaging (T-stage), nodal downstaging (N-status), complete
histopathologic response to neoadjuvant treatment (Dvorak regres-
sion grade 3 or 4), and grade 3 or 4 diarrhea or lymphopenia during
neoadjuvant treatment and adjuvant chemotherapy. Nonstratiﬁed
log-rank tests were performed to compare PFS and OS distributions
among the subgroups. Hazard ratio (HR) and 95% conﬁdence in-
tervals (CIs) were presented. Subgroup analyses for patients with R0-
resection versus all other patients was omitted because only 1 patient
was classiﬁed R1; all other patients were classiﬁed R0. For descriptive
reporting of patient-reported outcomes, the observation period was
divided into 6-month periods, starting at the date of surgery.
Results
Study Population
A total of 51 patients out of 54 patients (94%) who completed
the previously reported phase II study10 were included into this
prospective observational follow-up study. Three patients were lost
to follow-up because 1 out of 6 centers decided not to participate
in the follow-up study. Each patient was followed for at least
5 years after initial surgery for LARC (median follow-up, 70.2
months [95% CI, 70.8-74.1 months]). Patient characteristics are
summarized in Table 1. Of note, the predominantly male (40
patients; 78%) patient population consisted of high-risk patients
with T3 (46 patients; 90%) or T4 (5 patients; 10%), node-positive
(40 patients; 79%), moderately or poorly differentiated (49
patients; 96%) tumors. The lower rectum was involved in
17 patients (34%).Treatment
All patients underwent preoperative radiochemotherapy and
surgery, as previously reported.10 Results do not differ signiﬁcantly
from the previously reported entire study population with 11 pa-
tients (22%) achieving pathologic complete response, 22 patients
(43%) tumor downstaging, and 24 patients (47%) nodal down-
staging (Table 2). After surgery, 30 patients (59%) were treated
with adjuvant chemotherapy; almost half of them (14 patients;
47%) with a ﬂuoropyrimidine single agent regimen.
PFS and OS
At the time of analysis, 16 patients (32%) had been diagnosed
with recurrence of disease, and 4 patients (8%) had died (ie, a total
of 20 events for the primary endpoint PFS had occurred). Five-year
PFS and OS rates were 61% (95% CI, 46%-73%) and 78% (95%
CI, 63%-87%), respectively (Figure 1). A total of 31 patients (61%)
lived without recurrence of disease; the median PFS was not reached
but is longer than 77.9 months or 6.5 years (twenty-ﬁfth percentile
for PFS is 21.5 months). Similarly, the median OS was not reached,
with 39 patients (76%) being alive at the end of the observation
period.
Local recurrences occurred in 4 patients (8%) only. The distant
to local recurrence rate was 3:1. The median time to recurrence was
14.7 months (range, 7-65 months). The majority of patients
relapsed without symptoms (10 out of 16 patients).
In pre-planned univariate subgroup analyses, the main predictors
for prolonged PFS and OS were tumor downstaging and nodal
downstaging (Table 3). Whereas adjuvant chemotherapy (yes vs.
no) was a signiﬁcant adverse factor for recurrence, it was not for
survival (Table 3).
Long-Term Adverse Events
Bowel and Urinary Function. Seventeen (33%) of patients suf-
fered fecal incontinence, and 16 (31%) patients were dependentClinical Colorectal Cancer Month 2016 - 3
Figure 2 Self-Reported Long-Term Toxicity. A, Self-Reported Number of Bowel Movements per Day; B, Self-Reported Satisfaction With
Bowel and Urinary Function
A
B
Abbreviation: Pts ¼ patients.
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4 - Clion regular use of constipating agents during at least 1 of the
6-monthly observation periods. Urinary incontinence was re-
ported in 2 (4%) patients at one point during follow-up. The self-
reported number of bowel movements per day was higher than 3
for the majority of patients during the ﬁrst 3 years after initial
surgery (Figure 2A). Figure 2B shows satisfaction with urinary,
bowel, or stoma function for each observation period. Whereas
the number of patients for which data were available is variable
and diminishing over time, it shows that some patients are
dissatisﬁed for a very long time after treatment. As many as 14
(28%) of the 51 patients report “poor” or “very poor” satisfaction
with urinary, bowel, or stoma function during at least one
observation period.
Secondary Malignancies. Secondary malignant tumors were diag-
nosed in 6 patients. Three patients were curatively treated (carci-
noma of the skin [2 patients] and thyroid [1 patient]). Threenical Colorectal Cancer Month 2016patients received palliative treatment for a carcinoma of the stomach
(2 years after LARC), an esophageal carcinoma (3 years after
LARC), and a carcinoma of the posterior wall of the bladder (5 years
after LARC), respectively.
Adherence to Guidelines. For 90% of patients (N ¼ 46) a sur-
veillance scheme was intended, 78% according to FAGAS (Fach-
gesellschaft der Schweizer Gastroenterologen) and 12% according to
Swiss Society for Gastroenterology (SGG) Guidelines.16,17 Mean
compliance to the surveillance scheme was 40.6% (SD, 18.2%) (ie,
40.6% of all guideline-suggested follow-up exams were actually
completed).
Discussion
In this long-term follow-up report of a phase II study for patients
with LARC treated with preoperative radiochemotherapy, tumor
and nodal downstaging were the primary predictors of PFS (primary
Table 3 Relapse-Free and Overall Survival in Prespeciﬁed Subgroups (Univariate Analyses)
HR for Relapse 95% CI P Value HR for Survival 95% CI P Value
Age (60 years/>60 years) 1.04 0.43-2.51 NS 2.00 0.60-6.66 NS
Tumor downstaging 0.16 0.05-0.56 .0011 <0.01 <0.01-nr .0009
Nodal downstaging 0.17 0.06-0.52 .0005 0.18 0.04-0.83 .0131
pCR 0.38 0.09-1.65 NS 0.29 0.04-2.28 NS
Selected grade 3/4 toxicitiesa 0.72 0.30-1.73 NS 0.75 0.24-2.32 NS
Adjuvant chemotherapy 4.00 1.16-13.76 .0172 3.12 0.67-14.44 NS
Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio; NS ¼ not signiﬁcant (ie, P value above .05); pCR ¼ pathologic complete response (Dvorak histopathological regression grade 3 or 4).
aGrade 3 or 4 diarrhea or lymphocytopenia during neoadjuvant chemoradiation.
Viviane Hess et alendpoint) and OS. The local recurrence rate was 8%, and the local
to distant recurrence ratio was 1:3.
The trade-off for this high local control rate is signiﬁcant long-term
toxicity, with 28% of patients reporting poor or very poor satisfaction
with bowel, stoma, or urinary function, and 10% of patients expe-
riencing severe diarrhea (> 9 bowel movements per day), sometimes
years after primary treatment. Chronic diarrhea impacts on quality of
life on many levels: it adversely affects functioning in relationships
and job performance and leads to social isolation and depression.18,19
The main weakness of our study is the limited number of patients.
Therefore our conclusions are merely hypothesis-generating. Also,
during the follow-up time of our study, oxaliplatin was not estab-
lished as a component of preoperative radiochemotherapy in LARC,
because efﬁcacy results remain conﬂicting despite at least 5 large
phase III trials.14,20-23 However, except for peripheral neuropathy,
toxicity as compared with ﬂuoropyrimidine alone was similar;
therefore, our conclusions are generalizable to ﬂuoropyrimidine-based
radiochemotherapy in general.24 Furthermore, the patient-reported
outcomes were not collected with well-established standardized
questionnaires (eg, European Organization for Research and Treat-
ment of Cancer Quality of life questionnaires25), but with simple yes/
no questions or estimations on 4-point scales (very poor, poor, good,
very good). This approach was chosen in order to simplify the pro-
cedures; acknowledging that any result in our small and non-
controlled trial population would need to be conﬁrmed in a larger
setting. The strengths of our study are the prospectively planned
follow-up time for more than 5 years in a homogeneous trial pop-
ulation, looking not only at efﬁcacy parameters but also at long-term
toxicity including patient-reported outcomes.
Local relapses in less than 10% of patients is in line with pub-
lished long-term follow-up results of the German trial CAO/ARO/
AIO-94 (Surgical (CAO), radiooncological (ARO) and medical
(AIO) oncology working groups of the German Cancer Society) and
the European Organization for Research and Treatment of Cancer
Quality (EORTC) 22921 trial, both landmark studies in the treat-
ment of LARC.6,7,26,27 Detailed analyses of long-term treatment
sequelae and particularly patient-reported outcomes were not part of
these studies. With a median follow-up of 50 months, chronic grade
3 or worse diarrhea (in 7% and 9% of patients in the experimental
and control arms, respectively) and fecal incontinence (in 6% of
patients) were identiﬁed as the most frequent late toxicities in the
German CAO/ARO/AIO-04 trial.22 Documentation of toxicities
within clinical trials over extended periods of time consumes a large
amount of resources (staff, time, money). Similarly, planning a long-
term follow-up of patient-reported outcomes is often not part of aninitial clinical study protocol: not only more resources are needed
but an increase in number of missing data over time and therefore a
decrease in the robustness of any conclusion is feared. However, if
the clinical problem is signiﬁcant—and our data and that of others
conﬁrm this—methods need to be adapted to tackle it anyway.
In summary, our report emphasizes that only long-term follow-
up allows for weighing risks and beneﬁts of curatively intended
combined-modality treatment for LARC. Radiochemotherapy fol-
lowed by surgery results in a high local control rate (8% local re-
currences in our high-risk population). However, this stands at odds
with a high rate of patient-reported dissatisfaction with local func-
tion. Long-term follow-up, preferably including patient-reported
outcomes, should be mandatory in future trials for LARC, and
predictors for long-term toxicity are urgently needed. Furthermore,
the ongoing efforts to de-escalate local treatment for selected pa-
tients (PROSPECT trial: Chemotherapy Alone or Chemotherapy
Plus Radiation Therapy in Treating Patients With Locally Advanced
Rectal Cancer Undergoing Surgery)28 will be key to individualize
the balance between treatment (long-term) toxicity and efﬁcacy.Clinical Practice Points
 The local control rate for patients with LARC is high after
multimodal treatment, especially for patients with tumor or
nodal downstaging.
 The toxicity of multimodal treatment, and therefore the overall
beneﬁt/risk ratio, can only be fully assessed after long-term
follow-up.
 A proportion of patients need long-term specialized care for
gastrointestinal and/or urinary dysfunction after multimodal
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